✓ Medically reviewed✍️ HairBase editorial team📅 Last updated: June 14, 2026⏱ 1 min read
💡 Quick answer
Dutasteride is a 5-alpha-reductase inhibitor that, unlike finasteride (which blocks only type II), inhibits both the type I and type II isoenzymes . This p
As an AliExpress affiliate, we may earn a commission from qualifying purchases.
Evidence B · Promising
Dutasteride is a 5-alpha-reductase inhibitor that, unlike finasteride (which blocks only type II), inhibits both the type I and type II isoenzymes. This produces a more powerful reduction in DHT — roughly three times more potent against type II than finasteride, and far more so against type I. Its regulatory status varies by region: it is formally approved for hair loss in South Korea and Japan, while in the US and EU it is approved only for benign prostate enlargement and used off-label for AGA. Its evidence tier is therefore best described as promising rather than firmly established.
Like other 5AR inhibitors, it needs 4 to 12 months of consistent use before its effect can be judged, and the benefit fades if you stop. It has a longer half-life than finasteride, meaning it stays in the body longer, and its sexual side-effect profile is broadly similar.
Pregnancy warning: dutasteride is also teratogenic and can harm a developing male fetus, so women who are or may become pregnant must not take it or even handle broken capsules. The long half-life is also why blood donation is typically avoided for a period after stopping, so always discuss with a clinician whether this drug is appropriate for your situation before starting.
Dutasteride is one piece — build the whole plan
See how it ranks against every option, tuned to your stage, goal and budget.
2002FDA approves oral dutasteride (Avodart, 0.5 mg) — a dual type I/II 5-alpha-reductase inhibitor — for benign prostatic hyperplasia, establishing the molecule and safety profile later repurposed off-label for hair loss.
2006Olsen et al. publish the first major randomized placebo-controlled dose-ranging trial of dutasteride vs finasteride for male pattern hair loss in JAAD, demonstrating dose-dependent hair regrowth and superiority of higher-dose dutasteride to finasteride.
2009South Korea becomes the first country to approve oral dutasteride 0.5 mg/day specifically for male androgenetic alopecia (the indication remains off-label in the US/EU).
2015Japan's PMDA approves dutasteride 0.5 mg (Zagallo) for male androgenetic alopecia, the second national regulatory approval for this indication (Deliberation Results, Sept 2015).
2014Gubelin Harcha et al. publish the large pivotal phase IIb/III RCT (917 men) in JAAD confirming dutasteride 0.5 mg significantly outperforms finasteride 1 mg on 24-week hair count, supporting the approvals.
Dutasteride increased target-area hair count vs placebo in a dose-dependent manner; dutasteride 2.5 mg/day was superior to finasteride 5 mg/day at weeks 12 and 24, establishing that dual 5-alpha-reductase inhibition (lowering both scalp and serum DHT more completely) yields greater regrowth.
J Am Acad Dermatol (JAAD)
Gubelin Harcha et al., 20142014
Randomized, active- and placebo-controlled phase IIb/III RCT; 917 men aged 20-50, 24 weeks
Men received dutasteride 0.02/0.1/0.5 mg, finasteride 1 mg, or placebo daily. Hair count increased with dutasteride dose-dependently; dutasteride 0.5 mg significantly improved hair count, hair width and hair-growth assessment vs finasteride 1 mg at week 24 (reported P values ~.002-.004). This is the largest head-to-head trial and the basis for the Asian approvals.
153 Korean men aged 18-49, randomized to oral dutasteride 0.5 mg/day vs placebo for 6 months (phase III, double-blind, placebo-controlled)
Oral dutasteride 0.5 mg/day significantly increased hair counts vs placebo over 6 months (+12.2/cm2 vs +4.7/cm2, P=.0319), with improved subject and investigator/panel photographic assessments. Note: this was an oral trial (not mesotherapy) and was placebo-controlled (no in-trial finasteride comparator).
J Am Acad Dermatol (JAAD)
Herz-Ruelas et al., 20202020
Systematic review of 8 studies (5 oral, 3 intralesional/mesotherapy dutasteride)
Both oral and intralesional (mesotherapy) dutasteride improved hair count, but evidence for the injectable route was weak: mean hair-count increase was larger for oral (MD ~15.9 hairs) than intralesional (MD ~7.9 hairs in a single study). Authors concluded data were insufficient for reliable route comparison — intralesional dutasteride remains experimental with low-quality, heterogeneous evidence.
Skin Appendage Disord (PMID 33313048)
Latest research: Recent work (2023-2026) focuses on alternative routes and dosing to keep dutasteride's potency while limiting systemic DHT suppression — including intralesional/mesotherapy dutasteride (a 2025 Journal of Cosmetic Dermatology systematic review/meta-analysis showed promising local hair-count gains but flagged small samples and high heterogeneity), low-dose 0.2 mg phase III trials, and intermittent (twice/thrice-weekly) oral regimens versus daily finasteride. A 2025 Bayesian network meta-analysis of ~33 RCTs also ranked oral dutasteride 0.5 mg/day as the most effective monotherapy for male AGA by 24-week hair density (highest SUCRA).
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Dutasteride blocks both 5AR isoenzymes and lowers DHT more strongly, but stronger suppression does not automatically mean better results or fewer side effects for everyone. In Korea both are available for hair loss, so the right choice depends on your side-effect history and goals and is best made with a clinician.
Which countries approve dutasteride for hair loss?
It is formally approved for androgenetic alopecia in South Korea and Japan. In the US and EU it is approved only for benign prostate enlargement and is prescribed off-label for hair loss, so how it's prescribed may differ depending on where you live.
What should I know about its long half-life?
Dutasteride stays in the body longer than finasteride, so some effect persists for a while even after you stop. This is why blood donation is usually avoided for a period after discontinuing, and why it's especially important that anyone who could become pregnant is not exposed to the drug. Discuss this fully with a clinician before starting.
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.